{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:52:17Z","timestamp":1791071537610,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05561-9","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:50:47Z","timestamp":1791024647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enabling evidence generation for extremely preterm neonates: the use of neonatal real-world data"],"prefix":"10.1038","author":[{"given":"Ryan","family":"Kilpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel G.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwaljit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"5561_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamapediatrics.2013.4604","volume":"168","author":"JL Stiers","year":"2014","unstructured":"Stiers, J. L. & Ward, R. M. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 168, 106\u2013108 (2014).","journal-title":"JAMA Pediatr."},{"key":"5561_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jpeds.2017.08.011","volume":"192","author":"RM Ward","year":"2018","unstructured":"Ward, R. M. et al. The need for pediatric drug development. J. Pediatr. 192, 13\u201321 (2018).","journal-title":"J. Pediatr."},{"key":"5561_CR3","doi-asserted-by":"crossref","unstructured":"Martin, J. A., Hamilton, B. E. & Osterman, M. J. K. Births in the United States, 2023 (NCHS Data Brief, 2024).","DOI":"10.15620\/cdc\/158789"},{"key":"5561_CR4","doi-asserted-by":"publisher","first-page":"e055924","DOI":"10.1136\/bmj-2021-055924","volume":"376","author":"AS Morgan","year":"2022","unstructured":"Morgan, A. S., Mendon\u00e7a, M., Thiele, N. & David, A. L. Management and outcomes of extreme preterm birth. Bmj 376, e055924 (2022).","journal-title":"Bmj"},{"key":"5561_CR5","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamapediatrics.2023.3487","volume":"177","author":"T Venkatesan","year":"2023","unstructured":"Venkatesan, T. et al. National trends in preterm infant mortality in the United States by race and socioeconomic status, 1995-2020. JAMA Pediatr. 177, 1085\u20131095 (2023).","journal-title":"JAMA Pediatr."},{"key":"5561_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2352-4642(25)00106-3","volume":"9","author":"D De Luca","year":"2025","unstructured":"De Luca, D. et al. The lancet child & adolescent health commission on the future of neonatology. Lancet Child Adolesc. Health 9, 578\u2013612 (2025).","journal-title":"Lancet Child Adolesc. Health"},{"key":"5561_CR7","doi-asserted-by":"crossref","unstructured":"Kilpatrick, R. & Greenberg, R. G. Making the most of missing data. Pediatrics 153, e2023064938 (2024).","DOI":"10.1542\/peds.2023-064938"},{"key":"5561_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamapediatrics.2013.4208","volume":"168","author":"MM Laughon","year":"2014","unstructured":"Laughon, M. M. et al. Drug labeling and exposure in neonates. JAMA Pediatr. 168, 130\u2013136 (2014).","journal-title":"JAMA Pediatr."},{"key":"5561_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03097-x","volume":"19","author":"C Mease","year":"2024","unstructured":"Mease, C. et al. Analysis of the first ten years of FDA\u2019s rare pediatric disease priority review voucher program: designations, diseases, and drug development. Orphanet J. Rare Dis. 19, 86 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"5561_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.593281","volume":"8","author":"M Toma","year":"2021","unstructured":"Toma, M. et al. Paediatric medicines in Europe: the paediatric regulation-is it time for reform? Front. Med. 8, 593281 (2021).","journal-title":"Front. Med."},{"key":"5561_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpeds.2021.08.075","volume":"240","author":"A Stark","year":"2022","unstructured":"Stark, A. et al. Medication use in the neonatal intensive care unit and changes from 2010 to 2018. J. Pediatr. 240, 66\u201371.e64 (2022).","journal-title":"J. Pediatr."},{"key":"5561_CR12","unstructured":"FDA Guidance for Industry: Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drugs and Biological Products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory (2024)."},{"key":"5561_CR13","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.siny.2022.101331","volume":"27","author":"TF Miller","year":"2022","unstructured":"Miller, T. F., Kaiser, A., Schmelter, T., Lippert, J. & Davis, J. M. Using real-world data in pediatric clinical trials: lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn. Semin Fetal Neonatal Med. 27, 101331 (2022).","journal-title":"Semin Fetal Neonatal Med."},{"key":"5561_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"153","author":"PE Stang","year":"2010","unstructured":"Stang, P. E. et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann. Intern Med. 153, 600\u2013606 (2010).","journal-title":"Ann. Intern Med."},{"key":"5561_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jpeds.2018.02.045","volume":"198","author":"JR Swanson","year":"2018","unstructured":"Swanson, J. R. et al. Neonatal intensive care unit length of stay reduction by heart rate characteristics monitoring. J. Pediatr. 198, 162\u2013167 (2018).","journal-title":"J. Pediatr."},{"key":"5561_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jpeds.2021.08.014","volume":"239","author":"EM Weiss","year":"2021","unstructured":"Weiss, E. M. et al. Parental enrollment decision-making for a neonatal clinical trial. J. Pediatr. 239, 143\u2013149.e143 (2021).","journal-title":"J. Pediatr."},{"key":"5561_CR17","doi-asserted-by":"publisher","first-page":"151634","DOI":"10.1016\/j.semperi.2022.151634","volume":"46","author":"KL Watterberg","year":"2022","unstructured":"Watterberg, K. L., Carlo, W. A., Brion, L. P., Cotten, C. M. & Higgins, R. D. Overview of the neonatal research network: history, contributions, challenges, and future. Semin Perinatol. 46, 151634 (2022).","journal-title":"Semin Perinatol."},{"key":"5561_CR18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.pcl.2012.07.007","volume":"59","author":"N Laventhal","year":"2012","unstructured":"Laventhal, N., Tarini, B. A. & Lantos, J. Ethical issues in neonatal and pediatric clinical trials. Pediatr. Clin. North Am. 59, 1205\u20131220 (2012).","journal-title":"Pediatr. Clin. North Am."},{"key":"5561_CR19","unstructured":"Center For Drug, E., Research, I. B., Center For Biologics, E. & Research, I. B. Rare Diseases: Considerations for the Development of Drugs and Biological Products: Guidance for Industry (Center for Drug Evaluation and Research, 2023)."},{"key":"5561_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clp.2018.05.007","volume":"45","author":"WD Barfield","year":"2018","unstructured":"Barfield, W. D. Public health implications of very preterm birth. Clin. Perinatol. 45, 565\u2013577 (2018).","journal-title":"Clin. Perinatol."},{"key":"5561_CR21","unstructured":"Goodman, D. C. et al. The Dartmouth Atlas of Neonatal Intensive Care. The Dartmouth Institute of Health Policy & Clinical Practice (2019)."},{"key":"5561_CR22","doi-asserted-by":"crossref","unstructured":"Schulman, J. in The Problem of Practice Variation in Newborn Medicine: Critical Insights for Evaluating and Improving Quality 1\u201310 (Springer, 2022).","DOI":"10.1007\/978-3-030-94655-5_1"},{"key":"5561_CR23","doi-asserted-by":"publisher","first-page":"e2513274","DOI":"10.1001\/jamanetworkopen.2025.13274","volume":"8","author":"JA Rogowski","year":"2025","unstructured":"Rogowski, J. A. et al. Outcomes for very preterm infants across health systems. JAMA Netw. Open 8, e2513274 (2025).","journal-title":"JAMA Netw. Open"},{"key":"5561_CR24","doi-asserted-by":"publisher","first-page":"i2976","DOI":"10.1136\/bmj.i2976","volume":"354","author":"J Zeitlin","year":"2016","unstructured":"Zeitlin, J. et al. Use of evidence based practices to improve survival without severe morbidity for very preterm infants: results from the EPICE population based cohort. BMJ 354, i2976 (2016).","journal-title":"BMJ"},{"key":"5561_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/s-0039-1688477","volume":"10","author":"CP Hornik","year":"2019","unstructured":"Hornik, C. P. et al. Creation of a multicenter pediatric inpatient data repository derived from electronic health records. Appl. Clin. Inf. 10, 307\u2013315 (2019).","journal-title":"Appl. Clin. Inf."},{"key":"5561_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jamia\/ocad247","volume":"31","author":"C Reich","year":"2024","unstructured":"Reich, C. et al. OHDSI standardized vocabularies\u2014a large-scale centralized reference ontology for international data harmonization. J. Am. Med. Inform. Assoc. 31, 583\u2013590 (2024).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"5561_CR27","doi-asserted-by":"crossref","unstructured":"Essaid, S. et al. Mends-on-FHIR: leveraging the OMOP common data model and FHIR standards for national chronic disease surveillance. JAMIA Open 7, ooae045 (2024).","DOI":"10.1093\/jamiaopen\/ooae045"},{"key":"5561_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70106","volume":"34","author":"A Abellan","year":"2025","unstructured":"Abellan, A. et al. Expanding the OMOP common data model to support perinatal research in network studies. Pharmacoepidemiol. Drug Saf. 34, e70106 (2025).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"5561_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/ppul.26204","volume":"58","author":"LJ Kanbar","year":"2023","unstructured":"Kanbar, L. J. et al. Standardizing electronic health record ventilation data in the pediatric long-term mechanical ventilator-dependent population. Pediatr. Pulmonol. 58, 433\u2013440 (2023).","journal-title":"Pediatr. Pulmonol."},{"key":"5561_CR30","doi-asserted-by":"publisher","first-page":"e30970","DOI":"10.2196\/30970","volume":"9","author":"N Paris","year":"2021","unstructured":"Paris, N., Lamer, A. & Parrot, A. Transformation and evaluation of the MIMIC database in the OMOP common data model: development and usability study. JMIR Med. Inf. 9, e30970 (2021).","journal-title":"JMIR Med. Inf."},{"key":"5561_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10278-024-00982-6","volume":"37","author":"WY Park","year":"2024","unstructured":"Park, W. Y. et al. Development of medical imaging data standardization for imaging-based observational research: OMOP common data model extension. J. Imaging Inf. Med. 37, 899\u2013908 (2024).","journal-title":"J. Imaging Inf. Med."},{"key":"5561_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.201812-2348OC","volume":"200","author":"EA Jensen","year":"2019","unstructured":"Jensen, E. A. et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am. J. Respir. Crit. Care Med. 200, 751\u2013759 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"5561_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1221863","volume":"12","author":"AG Moreira","year":"2024","unstructured":"Moreira, A. G. et al. A clinical informatics approach to bronchopulmonary dysplasia: current barriers and future possibilities. Front. Pediatr. 12, 1221863 (2024).","journal-title":"Front. Pediatr."},{"key":"5561_CR34","doi-asserted-by":"crossref","unstructured":"Aleem, S. & Greenberg, R. G. The complex challenge of defining bronchopulmonary dysplasia. Pediatrics 156, e2025073156 (2025).","DOI":"10.1542\/peds.2025-073156"},{"key":"5561_CR35","doi-asserted-by":"publisher","first-page":"1340607","DOI":"10.3389\/fped.2023.1340607","volume":"11","author":"K Allegaert","year":"2023","unstructured":"Allegaert, K. et al. The neonatal adverse event severity scale: current status, a stakeholders\u2019 assessment, and future perspectives. Front. Pediatr. 11, 1340607 (2023).","journal-title":"Front. Pediatr."},{"key":"5561_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/archdischild-2024-328133","volume":"110","author":"S Peart","year":"2025","unstructured":"Peart, S. et al. Research priorities for the most premature babies born <25 weeks\u2019 gestation: results of an international priority setting partnership. Arch. Dis. Child Fetal Neonatal Ed. 110, 556\u2013563 (2025).","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"key":"5561_CR37","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.13063\/2327-9214.1244","volume":"4","author":"MG Kahn","year":"2016","unstructured":"Kahn, M. G. et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS 4, 1244 (2016).","journal-title":"EGEMS"},{"key":"5561_CR38","unstructured":"European Medicines Agency. Real-world evidence framework to support EU regulatory decision-making: report on the experience gained with regulator-led studies from September 2021 to February 2023. EMA\/289699\/2023. Amsterdam: European Medicines Agency;2023. https:\/\/www.ema.europa.eu\/en\/documents\/report\/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained_en.pdf."},{"key":"5561_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-02073-6","volume":"23","author":"J Weaver","year":"2023","unstructured":"Weaver, J. et al. Development and evaluation of an algorithm to link mothers and infants in two us commercial healthcare claims databases for pharmacoepidemiology research. BMC Med. Res. Methodol. 23, 246 (2023).","journal-title":"BMC Med. Res. Methodol."},{"key":"5561_CR40","doi-asserted-by":"crossref","unstructured":"Brewster, R. et al. Early discontinuation, results reporting, and publication of pediatric clinical trials. Pediatrics 149, e2021052557 (2022).","DOI":"10.1542\/peds.2021-052557"},{"key":"5561_CR41","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/pds.4975","volume":"29","author":"M Burcu","year":"2020","unstructured":"Burcu, M. et al. Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms. Pharmacoepidemiol. Drug Saf. 29, 1228\u20131235 (2020).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"5561_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40264-020-00944-1","volume":"43","author":"CM Gray","year":"2020","unstructured":"Gray, C. M., Grimson, F., Layton, D., Pocock, S. & Kim, J. A framework for methodological choice and evidence assessment for studies using external comparators from real-world data. Drug Saf. 43, 623\u2013633 (2020).","journal-title":"Drug Saf."},{"key":"5561_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/cpt.2994","volume":"114","author":"RPA van Eijk","year":"2023","unstructured":"van Eijk, R. P. A. et al. Hybrid controlled clinical trials using concurrent registries in amyotrophic lateral sclerosis: a feasibility study. Clin. Pharmacol. Ther. 114, 883\u2013892 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"5561_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","volume":"55","author":"M Jahanshahi","year":"2021","unstructured":"Jahanshahi, M. et al. The use of external controls in FDA regulatory decision making. Ther. Innov. Regul. Sci. 55, 1019\u20131035 (2021).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"5561_CR45","unstructured":"Food and Drug Administration. Considerations for the Design and Conduct of Externally. Controlled Trials for Drug and Biological Products. https:\/\/www.fda.gov\/regulatoryinformation\/ search-fda-guidance-documents\/considerations-design-and-conductexternally-controlled-trials-drug-and-biological-products (2023)."},{"key":"5561_CR46","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n, M. A., Wang, W. & Leaf, D. E. Target trial emulation: a framework for causal inference from observational data. Jama 328, 2446\u20132447 (2022).","journal-title":"Jama"},{"key":"5561_CR47","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMp2113319","volume":"385","author":"MA Hern\u00e1n","year":"2021","unstructured":"Hern\u00e1n, M. A. Methods of public health research - strengthening causal inference from observational data. N. Engl. J. Med. 385, 1345\u20131348 (2021).","journal-title":"N. Engl. J. Med."},{"key":"5561_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n, M. A., Sauer, B. C., Hern\u00e1ndez-D\u00edaz, S., Platt, R. & Shrier, I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J. Clin. Epidemiol. 79, 70\u201375 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"5561_CR49","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang, S. V. et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 1376\u20131385 (2023).","journal-title":"JAMA"},{"key":"5561_CR50","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns, G. L. et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157\u20131167 (2003).","journal-title":"N. Engl. J. Med."},{"key":"5561_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00431-019-03556-9","volume":"179","author":"L Schrier","year":"2020","unstructured":"Schrier, L. et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European Society for Developmental Perinatal and Pediatric Pharmacology. Eur. J. Pediatr. 179, 839\u2013847 (2020).","journal-title":"Eur. J. Pediatr."},{"key":"5561_CR52","doi-asserted-by":"publisher","unstructured":"Kilpatrick, R., Chaudhary, N., Eze-Njoku, C. et al. Environmental exposures in the neonatal intensive care unit impacting neurodevelopmental outcomes for neonates. Pediatr Res https:\/\/doi.org\/10.1038\/s41390-025-04743-1 (2025).","DOI":"10.1038\/s41390-025-04743-1"},{"key":"5561_CR53","unstructured":"Office of the Commissioner, O. o. C. P. a. P., Development, O. o. O. P., Research, C. f. D. E. a. & Research, C. f. B. E. a. (Administration, U. S. F. a. D. ed. (2019)."},{"key":"5561_CR54","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41587-022-01357-4","volume":"40","author":"JOB Jacobsen","year":"2022","unstructured":"Jacobsen, J. O. B. et al. The Ga4gh phenopacket schema defines a computable representation of clinical data. Nat. Biotechnol. 40, 817\u2013820 (2022).","journal-title":"Nat. Biotechnol."},{"key":"5561_CR55","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jval.2022.09.001","volume":"25","author":"SV Wang","year":"2022","unstructured":"Wang, S. V. et al. Harmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ispe\/ispor task force. Value Health 25, 1663\u20131672 (2022).","journal-title":"Value Health"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05561-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:03:33Z","timestamp":1791068613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05561-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":55,"alternative-id":["5561"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05561-9","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kilpatrick, Boyce, and Singh do not have any conflicts of interest to report. Rachel Greenberg has received support from industry for research services (\n                      \n                      ). Jonathan Davis is a consultant for Inflection Medicine.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}